NCT03973879View on ClinicalTrials.gov

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 29, 2020

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Malignant Glioma
Interventions
BIOLOGICAL

PVSRIPO

Oncolytic polio/rhinovirus recombinant

DRUG

Atezolizumab

Antibody

Sponsors
All Listed Sponsors
collaborator

Istari Oncology, Inc.

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Darell Bigner

OTHER